Fewer than a tenth of individuals eligible to benefit from GLP-1 drugs like Wegovy have access to them, caution the global health agency as it publishes its first recommendations on the medications.
Considering in excess of 1,000,000,000 people worldwide now obese, it is calling for increased and just access to GLP-1 medication.
According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"Our new guidelines affirms that obesity is a chronic disease that can be treated with comprehensive and ongoing care," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant hurdles to broad availability to the injections that can assist patients in reducing significant body mass, notes the body.
Skinny Jab Scarcity
Even under the present most favorable case, the production of such drugs could only cover about 100 million people – less than 10% of those who need them, according to the WHO.
The advice calls on nations and manufacturers to increase access, by approaches like voluntary licensing.
Exclusive production rights on a key compound – the main ingredient of a leading brand – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Jabs Function
GLP-1 drugs mimick a biological compound to reduce digestion speed, reduce hunger and increase feelings of fullness so individuals reduce food intake.
Individuals usually begin shedding pounds after several weeks of starting on the regular doses.
Research suggests patients may regain a significant portion after a year of stopping the drug, because their usual appetite resume.
To be carrying excess weight elevates your chance for experiencing diseases, like diabetes, heart disease, stroke, and specific malignancies.
Obesity affects individuals in all nations and was responsible for 3.7 million fatalities worldwide in 2024, as per the health agency.
